GSK 484
Alternative Names: GSK-4024484; GSK-484; MMV-1793192Latest Information Update: 02 Jan 2024
At a glance
- Originator GSK; Medicines for Malaria Venture
- Class Antimalarials; Pyrazines
- Mechanism of Action Cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malaria
Most Recent Events
- 22 Dec 2023 Preclinical trials in Malaria in Switzerland (unspecified route) prior to December 2023 (MMV pipeline, December 2023)
- 14 Dec 2023 Preclinical trials in Malaria in United Kingdom (unspecified route), prior to December 2023 (MMV pipeline, December 2023)
- 12 Dec 2023 Phase-I clinical trials in Malaria (In volunteers) in United Kingdom (PO) (NCT06171113) (GlaxoSmithKline pipeline, February 2024)